



AUSTRALIA
QUEENSLAND
of OPPORTUNITY

Queensland Clinical Trials Directory

A full ecosystem overview of service providers and sites in
Queensland, Australia

TIO TRADE +
INVESTMENT
QUEENSLAND



Queensland
Government
Australia

In consultation with Queensland Health and Department of State Development, Infrastructure and Planning



Contents

| | |
|--|-----------|
| About Trade and Investment Queensland | 1 |
| Why global sponsors choose Australia | 2 |
| Navigating the Australian clinical trials ecosystem | 4 |
| Key regulator and schemes | 4 |
| Clinical trials funding in Australia | 5 |
| Funding at a glance in Australia | 5 |
| Sources of funding | 5 |
| Private capital funding in Australia | 5 |
| Transforming health through clinical trials in Queensland | 6 |
| Queensland clinical trial sites | 8 |
| Major public clinical trial sites in Queensland | 9 |
| Queensland private and non-public clinical trial sites | 16 |
| Queensland service provider directory | 24 |
| Accounting/Tax/Business advisory | 24 |
| Contract Development and Manufacturing (CDMO) | 25 |
| Clinical Research Organisations (CROs) | 25 |
| Funding/Venture Capital | 28 |
| Human Research Ethics Committees (HRECs) | 28 |
| Insurance | 28 |
| Legal/Intellectual Property (IP) | 29 |
| Logistics | 30 |
| R&D Financing/Financing Options | 30 |
| Regulatory | 31 |
| Recruitment/Talent | 31 |
| Tools and Enabling Technology | 32 |
| Toxicology/Analytics | 34 |
| Training | 35 |
| Queensland industry support | 37 |
| Queensland service provider index | 38 |
| References and resources | 40 |
| Further information | 42 |
| Contribute to future editions | 42 |



About Trade and Investment Queensland

Trade and Investment Queensland (TIQ) is the Queensland Government's dedicated agency for facilitating international trade and investment.

As part of our health and life sciences strategy, TIQ actively positions and promotes Queensland as a globally competitive location for clinical trials, supporting sponsors across pharmaceuticals, biotech, medtech, and digital health.

Trade and Investment Queensland (TIQ) maintains a global footprint of trade and investment offices across 18 markets, including North America, Europe, Asia, and the Middle East. This international presence enables TIQ to actively connect Queensland's clinical trial capabilities with global sponsors, investors, and innovation partners.

Supporting Clinical Trials in Queensland

TIQ's **Health and Innovation Team (HIT)** offers tailored assistance to international sponsors considering Queensland for their next study. We provide **free, no-obligation pre-feasibility support** to assess business case viability for conducting trials in the state.

This includes:

- A customised pre-feasibility business case based on your protocol.
- Site and investigator identification aligned to therapeutic area.
- Guidance on start-up timelines, recruitment potential, and operational landscape.
- Connections to both public and private sector stakeholders across Queensland's trial ecosystem.

TIQ works in close partnership with **Queensland Health's Health Service Evaluation, Research and Translation Branch, within Clinical Excellence Queensland.**

Together, TIQ and Queensland Health help international sponsors de-risk their entry into Australia, offering a coordinated, expert-led engagement model to support trial success from planning through to start-up.

Contact us

North America Sponsor enquiries: alita.singer@tiq.qld.gov.au

Rest of World enquiries: shelly.lewis@tiq.qld.gov.au

If you would like your Queensland-based clinical trial site or service offering to be included in future updates, please contact: alita.singer@tiq.qld.gov.au



Why global sponsors choose Australia

Australia is globally recognized as a premier destination for clinical trials, offering sponsors a range of advantages that support both speed and quality.

R&D Tax Incentive

Eligible sponsors may access a generous **43.5% refundable R&D Tax Incentive**, significantly reducing the net cost of clinical research in Australia. This makes the country highly attractive for early-phase and proof-of-concept trials.



Efficient regulatory pathway

Australia's regulatory framework enables rapid trial start-up, with most Phase I–III trials requiring only ethics approval and a notification to the regulatory authority. This can reduce trial activation timelines by several months compared to other jurisdictions.

Australia's **National Mutual Acceptance (NMA)** scheme further streamlines this process by allowing a single ethics review to be accepted across multiple participating public health organisations nationally. This reduces duplication and accelerates multi-site trial activation.

Cost-effective and high quality

Australia offers **globally competitive trial costs** without compromising on quality. Trials are conducted under **ICH-GCP standards**, and the country has a well-trained, English-speaking workforce and internationally accredited sites.

Diverse and representative population

Queensland in particular offers access to a **diverse and multicultural patient population**, including urban, regional, and Indigenous communities—supporting inclusive recruitment strategies and meaningful real-world data generation.

Political and economic stability

Australia offers a highly stable political environment, robust healthcare infrastructure, and strong rule of law—providing sponsors with **predictability, safety, and long-term confidence** for investment in clinical research.

Gateway to the Asia-Pacific region

Strategically located in the Asia-Pacific, Australia serves as a **launchpad into fast-growing regional markets**. Many global sponsors use Australia as a first-in-human or early-phase trial site before expanding to other countries in the region.

Favorable foreign exchange rates

The strength of the Australian dollar relative to the U.S. dollar and euro can lead to **substantial cost savings** for overseas sponsors without compromising on quality.

Strong IP protection and data privacy

Australia has **world-class intellectual property (IP) protection laws**, aligned with global standards. Combined with strict **data privacy regulations**, this ensures that sponsors can conduct trials with confidence in the security of proprietary information.

Stringent governance and ethical oversight

Clinical trials in Australia are governed by **highly transparent and ethically rigorous frameworks**, including oversight by registered Human Research Ethics Committees (HRECs) and compliance with ICH-GCP and ISO 14155 standards, giving sponsors assurance of scientific integrity and participant safety.

Internationally-accepted clinical data

Clinical trials conducted in Australia are recognized globally for their high quality and regulatory rigor. Australian generated data is **acceptable by major international regulatory bodies**, including the **U.S. Food and Drug Administration (FDA)** and the **European Medicines Agency (EMA)**. This allows sponsors to use Australian clinical trial data to support **Investigational New Drug (IND)** applications, global Phase II/III programs, and marketing submissions without the need to repeat studies in other jurisdictions.

This global alignment provides sponsors with a **cost-effective and accelerated pathway to global markets**, particularly for early-phase and first-in-human trials.



Clinical trials conducted in Australia are recognised globally for their high quality and regulatory rigor.


Queensland's clinical trials ecosystem



A collaborative state-wide ecosystem of public and private trial capabilities supported by government and ICH-GCP standards.

Fast regulatory pathway

Trial activation in weeks, not months.



R&D Tax Incentive

Reduce clinical trial costs by 43.5%. Refundable R&D Tax Offset.



Gateway to Asia-Pacific

Strategic access to the Asia-Pacific region.

Favorable exchange rate

Exchange rate supports cost savings.



Patient access and diversity

Multicultural and regionally diverse population. Access to urban, rural and Indigenous communities.



Globally accepted by major regulations

Clinical trial data generated in Australia is routinely accepted by key international regulatory authorities, including the U.S. FDA, European Medicines Agency (EMA), Japan's PMDA and the UK's MHRA.



Patient recruitment

Patient identification in weeks, not months.

Navigating the Australian clinical trials ecosystem

Key regulator and schemes

Therapeutic Goods Administration

The [Therapeutic Goods Administration \(TGA\)](#) is Australia's national regulator for therapeutic goods, including medicines, vaccines, medical devices, and biologicals.

It is part of the Australian Government Department of Health and Aged Care, and ensures that therapeutic products available in Australia are safe, effective, and high quality.

The [Australian Register of Therapeutic Goods \(ARTG\)](#) is the public database of therapeutic goods that can be legally supplied in Australia. You can search the ARTG to find details of therapeutic goods approved for supply.

The TGA plays a critical regulatory role in the assessment and monitoring of [product](#), and in the conduct of clinical trials involving unapproved therapeutic goods in Australia.

As with many aspects of the regulatory framework, there are situations where special policies have been developed in response to the needs of particular people or circumstances. One such area is clinical trials. [Clinical trials](#) involving unapproved therapeutic goods may be conducted in Australia under two schemes: Clinical Trial Notification or Clinical Trial Approval.

Clinical Trial Notification (CTN) Scheme

The [CTN scheme](#) is Australia's most commonly used regulatory pathway for clinical trials involving unapproved therapeutic goods. Under this streamlined model, the Therapeutic Goods Administration (TGA) is not required to review clinical data prior to the trial commencing. Instead, responsibility for the scientific and ethical evaluation lies with a registered Human Research Ethics Committee (HREC). Once HREC approval is granted, the sponsor simply notifies the TGA, enabling faster trial start-up times. The CTN scheme is widely used for Phase I–III studies and is particularly attractive to international sponsors due to its efficiency, low regulatory burden, and global alignment with ICH-GCP and ISO 14155 standards.

Clinical Trial Approval (CTA) Scheme

The CTA scheme is a more detailed regulatory pathway used when a clinical trial involves higher-risk products or when a sponsor seeks TGA evaluation of preclinical and clinical data before commencing the trial. Under this model, the TGA conducts a thorough scientific assessment of the investigational product and must formally approve the trial

before it begins. Following TGA approval, the sponsor must also obtain HREC approval. The CTA pathway is typically used for novel therapies or trials where the safety profile is not well established, providing an additional layer of regulatory oversight and assurance.

In addition to its role in regulating trial approvals, the TGA also provides oversight across several other critical areas of clinical research. This includes ensuring compliance with Good Clinical Practice (GCP) standards, conducting inspections of trial sites – particularly those involved in manufacturing or handling investigational products – and offering guidance to sponsors and researchers through detailed regulatory frameworks and documentation. The TGA also plays a key role in verifying that all therapeutic goods used in trials, whether locally manufactured or imported, meet stringent quality and safety standards.

[National Mutual Acceptance \(NMA\)](#) is a streamlined ethical review system for multi-site clinical trials conducted in publicly funded health services across most Australian states and territories. Under the NMA scheme, a single Human Research Ethics Committee (HREC) approval is accepted by all participating institutions, reducing duplication and accelerating trial start-up. Trials conducted under the Clinical Trial Notification (CTN) or Clinical Trial Approval (CTA) schemes regulated by the Therapeutic Goods Administration (TGA) can benefit from NMA, enabling faster initiation of ethically approved trials across multiple jurisdictions.

The [National One Stop Shop \(NOSS\)](#) is a new Australian Government initiative under development, designed to streamline the approval and management of clinical trials and health-related human research across Australia. Once implemented, NOSS will provide a single, integrated digital platform for ethics applications, site-specific assessments, and trial registration reducing duplication, improving efficiency, and enhancing Australia's competitiveness as a destination for clinical research. This reform is part of a broader national effort to create a more consistent, coordinated and patient-accessible clinical trials environment.

Resource: The [Australian Clinical Trial Handbook](#) is a guide published by the Therapeutic Goods Administration (TGA) to support sponsors, researchers, and Human Research Ethics Committees (HRECs) in understanding the regulatory and ethical requirements for conducting clinical trials in Australia. It outlines processes for trial approvals, the use of investigational products, good clinical practice (GCP), and provides guidance on responsibilities under the Clinical Trial Notification (CTN) and Clinical Trial Approval (CTA) scheme.

Clinical trials funding in Australia

Funding at a glance in Australia

The National Health Medical Research Council Fund (NHMRCF) is the largest single source of direct government funding for clinical trials in Australia. It provides around A\$1 billion and Medical Research Future Fund provide \$650M in funding annually through a wide range of programs.

Clinical trials in Australia contributed approximately A\$1.6 billion to the Australian economy in 2022, representing approximately 22% of total spending on health research in Australia ([MTPConnect Australia's Clinical Trial Sector report, June 2024](#)).

Sources of funding

In Australia, the national [Clinical Trials Activity initiative](#) will provide A\$750 million over 10 years from 2024–25 to help Australian researchers and patients test new treatments through national and international clinical trials. It will also support research on rare cancers, rare diseases and unmet needs.

The initiative is funded by the [Medical Research Future Fund \(MRFF\)](#) and administered by [National Health and Medical Research Council \(NHMRC\)](#).

Private capital funding in Australia

Australia's innovation economy is underpinned by a hybrid funding model—government incentives (especially the R&D Tax Incentive) are foundational, but increasingly, private R&D capital providers play a crucial role in filling liquidity gaps and enabling earlier access to funding. These private financiers support startups, scale-ups, and established firms in biotechnology, healthtech, agtech, cleantech, and software sectors.



Main Types of Private R&D Capital

R&D Tax Incentive-backed advances

Short-term loans provided in anticipation of the company's future RDTI refund. Typically they advance up to 80-90% of the expected rebate; quarterly or milestone-based drawdowns available; and loan terms range from 3 to 12 months, repaid upon receipt of refund.

Venture debt with R&D collateral

Venture debt lines that combine traditional debt instruments with security against R&D claims. These are suited to more mature startups with revenue or institutional backing.

Revenue-Based Financing (RBF)

Emerging in early-stage ecosystems, RBF models allow firms to receive funding in exchange for a percentage of future revenue—less common but growing in software-heavy R&D environments.

Transforming health through clinical trials in Queensland

Queensland's clinical trials ecosystem

Queensland offers a dynamic and collaborative clinical trials ecosystem spanning the public and private sectors. The state is home to world-class hospitals, research institutes, Contract Research Organizations (CROs), and specialist service providers, all supported by a proactive state government committed to advancing medical innovation.

Queensland Health delivers an integrated public hospital network with a strong research focus, and with the private sector, contributes cutting-edge capabilities in trial design, execution, and analysis. Together, they form a robust environment for the efficient and high-quality delivery of clinical trials across all phases and therapeutic areas.



Queensland Health – public health system overview

Queensland Health oversees one of Australia's largest and most decentralized public healthcare systems, delivering high-quality care through **16 Hospital and Health Services (HHSs)** across the state. These public hospitals are integral to the clinical trials network, offering access to diverse patient populations, advanced facilities, and a skilled clinical workforce. With a strong emphasis on research and innovation, Queensland Health actively supports trials that improve health outcomes and accelerate access to emerging therapies for Queenslanders.

The Health Services Evaluation, Research and Translation (HSERT) branch plays a pivotal role in advancing Queensland Health by translating innovation and evidence into practice. It informs system-wide planning and decision-making through high-quality health services research, evaluation, and reporting. HSERT supports Hospital and Health Services (HHSs) and the Department in driving the uptake of ethical, high-quality research and clinical trials, with a focus on expanding access for First Nations people and those in rural, regional, and remote areas.

The branch streamlines ethics and governance processes and manages key platforms such as [DoRA 2.0 – Database of Research Activity](#), an open access online repository of Queensland Health publications and research activities and [Old Clinical Trials Portal](#). Additionally, HSERT fosters a culture of innovation and translation by investing in initiatives such as the Queensland Technology Future Fund and the Queensland Innovation Living Lab, which bring together clinicians, researchers, and industry to accelerate the adoption of innovative solutions across the health system.



Queensland Clinical Trials Consortium

The [Queensland Clinical Trials Consortium \(QCTC\)](#) is a collaborative initiative that unites over 200 clinical trial sites and more than 70 national and international companies across Queensland. This Consortium, led by Queensland Health, offers a comprehensive, end-to-end service platform for clinical research, encompassing areas such as finance, manufacturing, bioanalytics, preclinical and clinical operations, and regulatory affairs.

By fostering a coordinated network of public and private health providers, research institutions, and service partners, QCTC positions Queensland as a globally competitive destination for clinical trials. This integrated approach supports the design, execution, and regulatory submission of clinical studies across diverse therapeutic areas, thereby enhancing the state's capacity to attract and conduct high-quality, cost-effective research.

QCTC is promoted via the Queensland Government's [Queensland Clinical Trials Portal](#), a centralized digital resource for sponsors, researchers, and patients. The portal streamlines trial feasibility, site identification, and collaboration by connecting stakeholders across the public and private sectors. It showcases Queensland's capabilities and serves as a gateway for local and international organisations seeking to conduct or join trials in the state.



State-wide Pathology Network

[Pathology Queensland](#) is a statewide service delivering high-quality diagnostic and research laboratory services to public hospitals, clinics, and researchers. As one of Australia's largest public pathology providers, it plays a vital role in supporting clinical trials through its expertise in sample collection, analysis, and biobanking. The network ensures standardized, timely, and accredited pathology services, essential for clinical trial integrity and data quality.


Australian Teletrial Program

Access to clinical trials, closer to home



Australian Teletrials Program

Led by Queensland, the [Australian Teletrials Program](#) leverages telehealth and digital infrastructure to bring clinical trials to rural, regional, and remote communities. This innovative model ensures equitable trial access for patients outside major cities by connecting metropolitan principal investigators with local healthcare teams. The program enhances recruitment, reduces patient burden, and strengthens trial diversity while maintaining GCP-compliant oversight and governance.

 Royal Brisbane and Women's Hospital, Brisbane

Queensland clinical trial sites



Major public clinical trial sites in Queensland

Royal Brisbane and Women's Hospital (RBWH)

Queensland's largest public hospital and a flagship site within the Metro North Hospital and Health Service.

With a strong legacy in clinical excellence and innovation, RBWH serves as a major clinical trials and research hub, supporting a diverse portfolio of studies across oncology, neurology, infectious diseases, critical care, maternal and neonatal health, mental health, and surgical innovation.

RBWH has well-established clinical trial capabilities embedded within multiple departments and specialty units, enabling the delivery of early to late-phase trials, including first-in-human and complex interventional studies. It supports both investigator-led and commercially sponsored trials, with experienced clinician-researchers and dedicated research coordination teams ensuring high standards of compliance, recruitment, and patient care.

The hospital maintains extensive partnerships with leading academic institutions—most notably [The University of Queensland Centre for Clinical Research \(UQCCR\)](#), located adjacent to the RBWH campus at Herston. This close proximity facilitates seamless collaboration in translational medicine, clinical innovation, and emerging technologies such as genomics, imaging, and digital health.

RBWH's large and diverse patient population, combined with its robust clinical governance frameworks and proximity to Queensland's research infrastructure, make it a highly sought-after site for national and international sponsors seeking reliable and efficient clinical trial execution.


 [Royal Brisbane and Women's Hospital](#)



Photo: <https://www.metrosouth.health.qld.gov.au/hospital-and-health-centres/princess-alexandra-hospital>

Princess Alexandra Hospital (PAH)

One of Australia's foremost tertiary hospitals and a nationally recognised centre for clinical research and innovation. As a flagship facility of Metro South Health, PAH is a key site for clinical trials across multiple areas of strength, including oncology, liver disease, organ transplantation, infectious diseases, and regenerative medicine.

PAH is renowned for its expertise in complex and high-acuity care, making it a preferred location for early-phase and advanced clinical trials, including first-in-human studies. The hospital hosts several specialist trial units and supports both investigator-initiated and industry-sponsored research through experienced multidisciplinary teams.

A major advantage of PAH is its co-location with the [Translational Research Institute \(TRI\)](#)—a world-class biomedical research facility that brings together leading researchers from The University of Queensland, Queensland University of Technology, Mater Research, and Metro South Health. This unique integration fosters seamless collaboration between clinicians and scientists, accelerating the translation of research into real-world patient care.

 [Princess Alexandra Hospital](#)

PAH is renowned for its expertise in complex and high-acuity care.



Photo: <https://www.goldcoast.health.qld.gov.au/hospitals-and-centres/gold-coast-university-hospital>

Gold Coast University Hospital (GCUH)

GCUH is one of Queensland’s largest tertiary teaching hospitals and a key clinical trials hub in the state.

Actively engaged in research across emergency medicine, mental health, oncology, cardiology, and rehabilitation, GCUH supports a diverse portfolio of early to late-phase clinical trials. The hospital has strong academic and translational research ties through its collaboration with

[Griffith University](#) and the [Griffith Clinical Trials Unit](#), enhancing investigator-led and industry-sponsored studies through shared expertise and infrastructure.

GCUH is also a core partner in [Lumina, the Gold Coast Health and Knowledge Precinct \(GCHKP\)](#)—a vibrant innovation ecosystem that brings together health, science, and technology stakeholders to drive integrated research, education, and commercialisation outcomes.

This positioning makes GCUH an ideal site for collaborative, multidisciplinary clinical research with access to cutting-edge facilities and talent.

 [Gold Coast University Hospital](#)

Queensland Children’s Hospital (QCH)

QCH is the state’s flagship pediatric hospital and a national leader in specialized child and adolescent healthcare.

As the principal site of [Children’s Health Queensland](#), QCH is deeply committed to advancing pediatric research and plays a central role in conducting early to late-phase clinical trials across a range of complex and high-impact areas, including rare diseases, pediatric oncology, immunology, infectious diseases, neurodevelopmental disorders, and critical care.

QCH is home to a dedicated Clinical Trials Support Unit that provides streamlined coordination for investigator-initiated and industry-sponsored studies, ensuring child- and family-centered trial design and delivery. Its strong research partnerships—with institutions such as [QIMR Berghofer Medical Research Institute](#), [The University of Queensland](#), and [Queensland University of Technology](#)—enable integrated translational research pipelines from discovery to bedside.

As part of Queensland’s broader pediatric innovation network,



Photo: <https://www.statedevelopment.qld.gov.au/coordinator-general/state-development-areas/former-state-development-areas/qld-children-s-hospital-state-development-area>

QCH also collaborates on genomic medicine, digital health, and personalized therapeutics, contributing to globally recognised advances in child health. The hospital’s robust governance frameworks and established ethics processes further position it as a reliable and responsive site for pediatric trials of national and international significance.

 [Queensland Children’s Hospital](#)

Sunshine Coast University Hospital (SCUH)

A major tertiary referral hospital and the flagship of the Sunshine Coast Hospital and Health Service. As a rapidly expanding clinical and academic centre, SCUH is actively involved in clinical trials across cardiology, endocrinology (including diabetes), oncology, emergency medicine, infectious diseases, respiratory care, and mental health.

SCUH is strategically aligned with the [University of the Sunshine Coast \(UniSC\)](#) through collaborative research programs, academic appointments, and shared clinical training. This partnership fosters a strong translational research environment focused on addressing regional health priorities while advancing global research standards.

The hospital hosts a dedicated Research and [Clinical Trials Unit](#), which provides infrastructure and governance support for both investigator-initiated and industry-sponsored trials. SCUH is also positioned as a central hub for research across Queensland's growing coastal and hinterland regions, offering access to a large and diverse patient population and supporting innovation in rural and regional health delivery.

 [Sunshine Coast University Hospital](#)

SCUH is a major tertiary referral hospital and the flagship of the Sunshine Coast Hospital and Health Service.



Photo: <https://www.sunshinecoast.health.qld.gov.au/hospitals-and-health-centres/sunshine-coast-university-hospital>

Townsville University Hospital (TUH)

Largest tertiary referral and teaching hospital in North Queensland and a vital clinical research hub for the region.

As part of the Townsville Hospital and Health Service, TUH delivers advanced specialist care while supporting a broad spectrum of clinical trials across oncology, cardiology, surgery, infectious diseases, mental health, and Indigenous health.

TUH plays a critical role in bridging urban and regional healthcare delivery through its strategic focus on trial accessibility and population diversity. It serves as a central site for research that addresses the health challenges of regional, rural, and remote communities, as well as culturally appropriate models of care for Aboriginal and Torres Strait Islander peoples.

The hospital has strong academic and research ties with [James Cook University \(JCU\)](#), particularly through the [Australian Institute of Tropical Health and Medicine \(AITHM\)](#). These partnerships support a robust translational research ecosystem spanning tropical medicine, antimicrobial resistance, public health, and chronic disease management relevant to northern Australia and the broader Asia-Pacific region.

TUH is equipped with dedicated research governance teams and clinical trial coordination infrastructure to support investigator-led and commercially sponsored studies. Its unique geographical reach, research expertise, and strong university linkages make TUH a strategic site for sponsors seeking to conduct trials that are both globally relevant and regionally impactful.

 [Townsville University Hospital](#)

TUH is the largest tertiary referral and teaching hospital in North Queensland and a vital clinical research hub for the region.



Photo: <https://www.cairns-hinterland.health.qld.gov.au/hospitals-and-health-centres/cairns-hospital>

Cairns Hospital

Major regional referral centre in Far North Queensland and plays a pivotal role in delivering specialized healthcare and advancing clinical research across the tropical north. As part of the Cairns and Hinterland Hospital and Health Service, the hospital serves a diverse population spanning urban, rural, and remote communities—including significant Aboriginal and Torres Strait Islander populations—and is a key driver of regionally relevant, inclusive research.

Cairns Hospital is actively engaged in clinical trials across tropical medicine, infectious diseases, endocrinology (including diabetes), respiratory health, and Indigenous health research. Its location and catchment area position it as a valuable site for studies targeting diseases prevalent in tropical climates, such as dengue, tuberculosis, parasitic infections, and antimicrobial resistance.

The hospital collaborates closely with [James Cook University \(JCU\)](#) and the [Australian Institute of Tropical Health and Medicine \(AITHM\)](#) to advance translational research in global and tropical health. These partnerships provide access to academic expertise, laboratory infrastructure, and community-based research networks, enabling trials that are culturally sensitive, scientifically rigorous, and globally significant.

With growing investment in research infrastructure and a dedicated clinical trials support team, Cairns Hospital offers strong capabilities for both investigator-initiated and commercially sponsored studies, making it a strategic gateway for health research in Australia's tropical north and the Asia-Pacific region.



Mackay Base Hospital

Key regional health facility in Central Queensland and a growing hub for clinical research. As the principal referral hospital for the Mackay Hospital and Health Service, it supports a wide catchment spanning urban, coastal, and rural communities—making it well-positioned to deliver trials that reflect real-world patient diversity and regional health priorities.

The hospital is actively involved in clinical trials across diabetes, mental health, general medicine, cardiology, and women's health, with a strong focus on improving access to research for regional and underserved populations. Its trial activities support both investigator-led and commercially sponsored studies, contributing to improved health outcomes in areas where trial opportunities have traditionally been limited.

Mackay Base Hospital collaborates with local and national partners—including [COUniversity](#), [James Cook University \(JCU\)](#), and neighboring hospital and health services—to strengthen research capacity and drive innovation in public healthcare. Through these partnerships, the hospital contributes to a broader regional research network across central and north coastal Queensland.

With expanding research infrastructure, experienced clinicians, and a commitment to embedding research into clinical practice, Mackay Base Hospital is emerging as a valued site for sponsors seeking high-quality, community-engaged trial delivery in a regional context.



Key regional health facility in Central Queensland and a growing hub for clinical research.



Photo: <https://www.mackay.health.qld.gov.au/hospitals-and-health-centres/mackay-base-hospital>

The Prince Charles Hospital (TPCH)

Queensland's premier cardiopulmonary research hospital and one of Australia's most advanced centres for cardiac, thoracic, and transplant medicine. As part of the Metro North Hospital and Health Service, TPCH plays a central role in the delivery of cutting-edge clinical care and translational research across a range of complex and chronic conditions.

TPCH is internationally recognised for its leadership in clinical trials in heart failure, pulmonary hypertension, lung disease, cystic fibrosis, and heart and lung transplantation. The hospital conducts early- and late-phase trials, including investigator-led, cooperative group, and industry-sponsored studies aimed at improving diagnostics, treatment strategies, and patient outcomes in high-burden cardiopulmonary diseases.

The hospital is home to the [Cardiology Clinical Research Centre \(CCRC\)](#) and the [Queensland Lung Transplant Service \(QLTS\)](#)—both of which contribute significantly to national and global advancements in organ transplantation, mechanical circulatory support, and regenerative therapies. TPCH is also a leading site for extracorporeal life support (ECLS) and ECMO research, through its association with the internationally renowned [Critical Care Research Group \(CCRG\)](#).

TPCH maintains strong collaborative partnerships with [The University of Queensland \(UQ\)](#) and [QIMR Berghofer Medical Research Institute](#), supporting a thriving translational research environment in cardiopulmonary medicine and immunology. Its integrated model of clinician-led research, multidisciplinary expertise, and dedicated trial infrastructure make TPCH a preferred destination for sponsors and researchers seeking to advance novel therapies in respiratory and cardiovascular health.

 [The Prince Charles Hospital](#)

Queensland's premier cardiopulmonary research hospital and one of Australia's most advanced centres for cardiac, thoracic, and transplant medicine.

Logan Hospital

Major public health facility within the Metro South Hospital and Health Service and serves one of Queensland's fastest-growing and most diverse communities. The hospital plays a vital role in expanding access to clinical trials in outer-metropolitan and regional catchments, supporting research that reflects the real-world needs of a broad population base.

Logan Hospital is actively involved in clinical trials across maternity and perinatal care, diabetes and endocrinology, adolescent and youth health, emergency medicine, and general practice-linked care. With a strong focus on community health equity, Logan is well positioned to support trials targeting underrepresented groups, including culturally and linguistically diverse populations.

The hospital works in close partnership with [Griffith University](#) to advance collaborative research and training, and is supported by the [Metro South Health Clinical Trials Unit \(CTU\)](#), which provides end-to-end trial coordination, regulatory guidance, and governance support for both investigator-initiated and commercially sponsored studies.

 [Logan Hospital](#)

Major public health facility within the Metro South Hospital and Health Service and serves one of Queensland's fastest-growing and most diverse communities.



Artist impression. Photo: <https://www.metrosouth.health.qld.gov.au/hospital-and-health-centres/logan-hospital/logan-hospital-expansion>

Redcliffe Hospital and Caboolture Hospital

Key regional facilities within Queensland's Metro North Hospital and Health Service, serving rapidly growing urban and semi-rural communities north of Brisbane. Both hospitals are actively expanding their clinical research programs and play a vital role in improving healthcare access and innovation across the Moreton Bay region.

The hospitals support a diverse portfolio of clinical trials in aged care, chronic disease management, community and population health, emergency medicine, mental health, and women's and children's health. With a strong focus on real-world applicability and inclusive research, these sites are well positioned to deliver trials that reflect the health needs and challenges of suburban and regional populations.

Redcliffe and Caboolture Hospitals are increasingly participating in multi-centre research studies, including national investigator-led trials and commercially sponsored research. Their integration into broader networks across Metro North enables collaboration with tertiary centres such as the [Royal Brisbane and Women's Hospital](#) and [The Prince Charles Hospital](#), allowing access to specialist expertise, shared research governance frameworks, and coordinated study delivery.

The hospitals also promote grassroots clinical innovation, encouraging clinicians to lead and engage in research that enhances local models of care and health service delivery. Supported by dedicated research staff and aligned with Queensland Health's strategic commitment to building research capacity in regional and outer-urban areas, Redcliffe and Caboolture Hospitals are emerging as valuable contributors to Queensland's decentralized and scalable clinical trial network.

 [Redcliffe Hospital](#)

 [Caboolture Hospital](#)

Redcliffe and Caboolture Hospitals are increasingly participating in multi-centre research studies.



Photo: <https://www.westmoreton.health.qld.gov.au/hospitals-and-health-centres/ipswich-hospital>

Ipswich Hospital

Principal referral facility within [West Moreton Health](#) and a cornerstone of public healthcare delivery in Queensland's growing western corridor. Serving a diverse and expanding population across Ipswich, the Lockyer Valley, Somerset, and Scenic Rim regions, the hospital plays an important role in advancing regional research and improving access to clinical trials outside major metropolitan centres.

Ipswich Hospital conducts public clinical trials across a range of priority health areas, including mental health, aged care, chronic illness, diabetes, and respiratory disease. With a focus on real-world implementation and health equity, the hospital supports studies that address the specific needs of its local communities, many of whom experience higher rates of chronic and complex conditions.

Ipswich Hospital is working to integrate research more deeply into routine care pathways, thereby expanding patient access to novel therapies, particularly for those in semi-urban and rural areas west of Brisbane.

Through partnerships with universities and statewide research networks, Ipswich Hospital is strengthening its role within Queensland's decentralized research ecosystem. It is positioning itself as a valuable contributor to multi-site clinical trials and translational research aimed at improving outcomes for underserved populations.

 [Ipswich Hospital](#)

Principal referral facility within [West Moreton Health](#) and a cornerstone of public healthcare delivery in Queensland's growing western corridor.



Photo: <https://www.metrosouth.health.qld.gov.au/hospital-and-health-centres/qeii-jubilee-hospital>

Queen Elizabeth II Jubilee Hospital (QEII)


Key public healthcare facility in Brisbane’s southern suburbs and an important contributor to community-focused clinical research within the Metro South Hospital and Health Service. Serving a diverse and growing suburban population, QEII plays a strategic role in enhancing equitable access to clinical trials outside major tertiary centres.

The hospital supports small-to-medium scale clinical trials across rehabilitation, geriatrics, general medicine, musculoskeletal health, chronic disease, and community-based care. Its focus on functional recovery, healthy ageing, and integrated care models positions it well for trials targeting older adults and those managing long-term conditions.

QEII collaborates closely with other Metro South research-active hospitals—such as the [Princess Alexandra Hospital](#)—as well as with academic partners including [Griffith University](#) and [The University of Queensland](#). These collaborations help facilitate access to specialist expertise, ethics and governance support, and research training opportunities for clinicians.

[Queen Elizabeth II Jubilee Hospital](#)

Key public healthcare facility in Brisbane’s southern suburbs and an important contributor to community-focused clinical research within the Metro South Hospital and Health Service.



Queensland private and non-public clinical trial sites



Brain and Mind Hub

Brain and Mind Hub (BaMH):

Brain & Mind Hub (BaMH) operates specialist neuroscience and mental health clinics across Maroochydore and Noosaville on Queensland's Sunshine Coast. The Maroochydore site delivers integrated psychiatry, psychology, neurophysiology, pharmacogenomics, and advanced neuromodulation services, including TMS and QEEG-guided interventions, alongside clinical trials operations. The Noosaville site is a dedicated clinical trials and psychedelic-assisted therapy facility incorporating purposebuilt dosing suites, specialist medical consulting rooms, pharmacy infrastructure, and participant integration spaces. Across both locations, BaMH supports sponsor-led and investigator-initiated trials with capabilities in participant recruitment, precision diagnostics, real-world outcomes collection, and multidisciplinary clinical care.

Key areas: Neurology/Neurosciences, Psychiatry/Mental Health, Pain Management, We also trial novel treatment devices such as TMS, tDCS and other brain stimulation devices.

Phase/s: Phase II; Phase III, Phase IV



Coral Sea Clinical Research Institute

Coral Sea Clinical Research Institute (CSCRI):

Dedicated clinical research facility located within the Mater Medical Suites in North Mackay. Strategically positioned adjacent to the region's sole gastroenterological unit, CSCRI serves a well-defined population within a 400 km radius, addressing the needs of communities that have historically had limited access to clinical trials.

CSCRI has a core focus on gastroenterology. The institute collaborates with internationally recognized gastroenterologists and maintains a dedicated team of experienced investigators, sub-investigators, and research nurses to deliver high-quality, personalized care to regional patients.

Key areas: Gastroenterology incl: Coeliac Disease; Inflammatory Bowel Disease (IBD); Irritable Bowel Syndrome (IBS); and Other Gastrointestinal Disorders.

Phase/s: Phase II; Phase III



Gallipoli Medical
Research

Gallipoli Medical Research Clinical Trials Unit

Gallipoli Medical Research (GMR) Clinical Trials Unit:

Located within the Greenslopes Health Precinct in Brisbane, GMR is a leading independent research organisation dedicated to improving patient outcomes through high-quality clinical trials. GMR works in close collaboration with Ramsey Health Care Clinical Trials Network and the Greenslopes Private Hospital—one of Australia's largest private teaching hospitals—to provide patients with access to new and emerging trial medications.

GMR provides their sponsor research partners with first-class conduct, management and coordination of multi-centre clinical trials, with patient-focused care at the heart of everything they do.

Key areas: Oncology; Respiratory; Infectious Diseases; Gastroenterology; Hepatology; Psychiatry/Mental Health

Phase/s: Phase I; Phase II; Phase III



Griffith University Clinical Trial Unit

Griffith University Clinical Trial Unit (GUCTU): Purpose-built facilities and provides clinical trial site services to commercial clients. The unit has conducted >70 commercially funded clinical trials in various disease states and healthy volunteers, across rare and chronic conditions, with expertise in vaccine, device, PK and GMO trials. Its highly trained, multidisciplinary team is supported by a network of GPs, and private and public specialist clinicians leveraging multiple recruitment pathways.

Key areas: Cardiovascular; Respiratory; Neurology/Neurosciences; Endocrinology/Metabolic Disorders; Infectious Diseases; Immunology/Autoimmune; Gastroenterology; Hepatology; Psychiatry/Mental Health; Pain Management; Women's Health/Reproductive Health; Medical Devices; Rare Diseases; Healthy Volunteer Trials

Phase/s: Phase I; Phase II; Phase III; Phase IV

www.griffith.edu.au/clinical-trial-unit



Healthscope

Healthscope: One of Australia's largest private hospital networks, has multiple facilities across Queensland, including key locations in Brisbane, the Gold Coast, and regional centres. As part of its commitment to delivering high-quality patient care and supporting clinical innovation, Healthscope hospitals in Queensland actively participate in a range of clinical trials across specialist disciplines, in partnership with private practitioners, contract research organisations (CROs), and industry sponsors.

Healthscope's private hospital trial sites offer streamlined governance pathways, experienced clinical staff, and access to well-equipped hospital infrastructure, including operating theatres, day infusion units, and diagnostic imaging services. Trials are typically delivered in collaboration with site management organisations (SMOs) and supported by research coordinators embedded within specialist practices.

Key areas: Oncology; Haematology; Cardiometabolic Disorders; gastroenterology; Hepatology; Orthopedics and Musculoskeletal; Respiratory; Medical Devices and Surgical Innovation

Phase/s: Phase II; Phase III; Phase IV



Icon Group

Icon Group: A leading global provider of comprehensive cancer care, with a strong presence across Australia, New Zealand, Asia, and the UK. As the operator of Australia's largest private cancer clinical trials program, Icon Group is committed to increasing access to cutting-edge oncology treatments and advancing innovation in cancer care.

Icon's dedicated clinical trials program supports Phase I–IV studies, including global and multicenter trials, across a broad range of tumor types, collaborating with international pharmaceutical companies, biotechnology firms, cooperative research groups, and academic institutions to trial novel therapeutics, immunotherapies, targeted agents, and supportive care interventions.

With centralized ethics, governance, and monitoring systems, along with a highly experienced National research team, Icon offers a streamlined and scalable model for clinical trial delivery.

Key areas: Oncology

Phase/s: Phase I; Phase II; Phase III; Phase IV



James Cook University Clinical Trials

James Cook University (JCU) Clinical Trials: James Cook University (JCU), headquartered in Townsville and Cairns, is one of Australia's leading regional research institutions with a strong focus on improving health outcomes in tropical, rural, remote, and Indigenous communities. Through its Research and Innovation Services, JCU facilitates clinical trials in partnership with hospital and health services, national and international sponsors, and collaborative research networks.

JCU supports a decentralized and community-connected clinical trials ecosystem across northern Queensland, offering sponsors access to both metropolitan and underserved patient populations. Research activities are delivered in collaboration with regional hospitals, the Australian Institute of Tropical Health and Medicine (AITHM), and clinical training partners across the state. Its clinical research is closely integrated with academic disciplines and supported by research governance teams that ensure compliance, ethics, and operational readiness for clinical trial delivery.

Key areas: JCU conducts and supports clinical trials across a broad spectrum of health priorities relevant to tropical and regional Australia, including Tropical and Infectious Diseases; Chronic Disease Management; Respiratory and Environmental Health; Indigenous and Rural Health; Mental Health; Oncology; and Digital Health.

Phase/s: Phase I; Phase II; Phase III; Phase IV



John Flynn Private Hospital

John Flynn Private Hospital: Part of the Healthscope network, John Flynn is a leading private hospital located on the southern Gold Coast, near the Queensland–New South Wales border. Known for its commitment to excellence in specialist care, John Flynn supports a growing portfolio of clinical trials through collaborations with private specialists, research organisations, and contract research partners.

With a strong focus on integrating research into private healthcare, the hospital offers convenient access to innovative treatments for patients and supports clinical trials across both outpatient and inpatient settings. Trials at John Flynn are typically delivered in partnership with site management organisations (SMOs) and contract research organisations (CROs), ensuring streamlined trial delivery and high-quality data.

Key areas: Oncology; Haematology; Cardiology; Endocrinology and Metabolic Disorders; Gastroenterology; Respiratory; Orthopedics; Pain Management; Women's Health.

Phase/s: Phase I (depending on therapeutic area and sponsor requirements); Phase II; Phase III; Phase IV



Mater Research

Mater Research: Mater Research is a not-for-profit global leader in medical research, with a bench-to-bedside philosophy that encourages collaboration with clinicians across Mater's Queensland-wide network of both public and private hospitals and healthcare services.

Through Mater Clinical Trials (MCT), more than 200 active trials are conducted across Mater's diverse therapeutic areas, including pharmaceutical, device, and other interventional trials. MCT supports industry, collaborative groups and investigator initiated research with experienced, GCP-accredited staff and key opinion leading Principal Investigators. Sponsors benefit from streamlined start-up via Priority Trial Review, flexible ethics pathways, and access to infrastructure such as a clinical trials pharmacy, Mater Pathology, and hospital imaging services. MCT ensures highest standards of safety and data integrity, making it a trusted partner in Australia's research ecosystem for delivering efficient, compliant and impactful clinical trials.

Key areas: Oncology, Haematology and Palliative care; Neuroscience; Maternal and Neonatal health; Surgical and Critical Care; Respiratory and Infectious Diseases; Endocrinology; Gastroenterology and Hepatology; Nephrology; and healthy volunteer studies.

Phase/s: Phase 0; Phase I; Phase II; Phase III; Phase IV; Medical Device Pilot, Pivotal, Post-Market



Nucleus Network – Brisbane

Nucleus Network – Brisbane: Australia's largest dedicated early phase clinical trial operator with clinical trial units operating across Australia (Brisbane and Melbourne), the UK (London) and the USA (Minneapolis). Nucleus has conducted in excess of 2,500 clinical trials across various therapeutics areas and specialises in FIH SAD/MAD, POC, DDI, BA/BE, Vaccine, Biosimilar, renal impairment and ethnobridging studies.

Key areas: Cardiovascular; Respiratory; Neurology/Neurosciences; Endocrinology/Metabolic Disorders; Infectious Diseases; Immunology/Autoimmune; Gastroenterology; Hepatology; Dermatology; Rare Diseases

Phase/s: Phase I; Phase II; Phase III



Paratus Clinical

Paratus Clinical: Operates dedicated clinical trial sites in Brisbane and the Gold Coast, forming part of a national network committed to high-quality, efficient clinical trial delivery. These Queensland-based sites are staffed by experienced investigators and research teams and are strategically located to offer sponsors access to both urban and suburban patient populations across Southeast Queensland.

With a focus on streamlined start-up, participant-centric care, and strong recruitment performance, Paratus Clinical's sites are well-equipped to support a broad range of clinical trials across therapeutic areas and development stages. Their integrated site model ensures consistency, compliance, and scalability across studies.

Key areas: Cardiovascular; Respiratory; Endocrinology/Metabolic Disorders; Infectious Diseases; Gastroenterology; Pain Management; Women's Health/Reproductive Health; Medical Devices; Digital Healthcare

Phase/s: Pre-Clinical/Animal; Phase I; Phase II; Phase III; Phase IV



Pindara Private Hospital

Pindara Private Hospital: Located in Benowa on the Gold Coast, is part of the [Ramsay Health Care](#) network and is one of Queensland's largest and most comprehensive private hospitals. With a strong reputation for clinical excellence and access to a wide network of specialists, Pindara actively participates in industry-sponsored and investigator-initiated clinical trials in partnership with research organisations, CROs, and site management organisations (SMOs).

Pindara's clinical trial activities are integrated within the hospital's specialist departments and consulting suites, providing patients with access to emerging therapies and novel interventions within a high-quality private care environment. Its modern facilities, diverse patient population, and multidisciplinary teams make it a preferred site for conducting trials across a range of therapeutic areas.

Key areas: Oncology; Haematology; Cardiology; Endocrinology and Metabolic Disorders; Gastroenterology; Respiratory; Orthopedics; Pain Management; Reproductive/Women's Health; Urology/Men's Health

Phase/s: Phase II; Phase III; Phase IV. May also participate in pilot or feasibility studies, and contribute to early-phase trials in selected areas via affiliated networks or research units.



QIMR Berghofer Medical Research Institute – Clinical Trials and Research

QIMR Berghofer Medical Research Institute (QIMR) – Clinical Trials and Research: One of Australia’s leading translational research institutes, QIMR is located within the Herston Health Precinct in Brisbane. With a mission to better diagnose, prevent, and treat serious diseases, QIMR Berghofer plays a vital role in bridging laboratory discoveries with clinical application through its comprehensive clinical trials program and world-class scientific services.

QIMR Berghofer collaborates with clinicians, hospitals, and industry sponsors to support the delivery of early-phase and translational clinical trials, particularly those involving advanced therapeutics, immunotherapies, and personalized medicine. Its internal research strengths are matched by the institute’s integrated infrastructure, which supports every stage of the translational pipeline—from discovery and preclinical validation to clinical trial execution.

Key areas: Oncology and Immuno-oncology; Infectious Disease and Vaccines; Genetics and Rare Diseases; Neurology/Neuroscience; Mental Health; Inflammation, Chronic Disease and Metabolic Conditions; Public Health and Population Genomics.

Phase/s: Pre-Clinical; Phase I; Phase II; Phase III; Clinical Validation and Longitudinal Cohort Studies (for diagnostics, biomarkers, and long-term population health outcomes).

Scientific Services and Core Facilities

Scientific Services and Core Facilities – QIMR Berghofer provides an extensive range of scientific platforms and core services to support external partners, academic collaborators, and industry sponsor, such as Genomics and Transcriptomics Platforms - Whole-genome sequencing, RNA-Seq, single-cell sequencing, and high-throughput analytics; Flow Cytometry and Imaging - Multicolor flow cytometry, cell sorting, confocal microscopy, and histopathology services; Biostatistics, Bioinformatics, and Clinical Data Services - including trial design, statistical modelling, and real-world data analysis; and Biospecimen Collection and Biobanking - With access to well-annotated tissue and blood samples for translational research.

Q-Gen Cell Therapeutics

Q-Gen Cell Therapeutics is QIMR Berghofer’s Therapeutic Goods Administration (TGA)-licensed manufacturing facility, specialising in the production of Cell and gene therapies, including CAR-T cells, dendritic cells, and T-cell receptor therapies; GMP-compliant manufacture of cellular products for clinical trials and compassionate use; and Customised support for sponsors requiring scale-up, regulatory support, and product development in cell-based therapeutics. Q-Gen plays a vital role in advancing Australia’s sovereign capacity for developing and delivering advanced therapeutics, supporting early-phase trials at QIMR Berghofer and partner institutions across the country.

With its integrated ecosystem of discovery research, clinical translation, scientific platforms, and GMP manufacturing, QIMR Berghofer is uniquely positioned as a full-spectrum partner for clinical innovation, offering world-class capabilities for both early discovery and human application.

www.qimrb.edu.au/commercial-collaborations/q-gen



Queensland Eye Institute

Queensland Eye Institute – The Clinical Trials Unit (CTU) operates within Queensland’s largest private, not-for-profit ophthalmic institute, offering comprehensive support for both sponsor-driven and investigator-initiated clinical research. Our dedicated team provides end-to-end trial management, ensuring streamlined approvals, rapid recruitment, and high-quality trial governance. The institute setting offers unique advantages, including access to internationally recognised Principal Investigators across the full spectrum of ophthalmic subspecialties, state-of-the-art diagnostic and imaging capabilities, and integrated day hospital facilities. Together, these strengths enable the CTU to deliver high-quality, innovative clinical research that advances ophthalmic care locally and globally.

Key areas: Rare Diseases; Medical Devices; Ophthalmology

Phase/s: Phase I; Phase II; Phase III; Phase IV



Queensland University of Technology

Queensland University of Technology (QUT)

Queensland University of Technology (QUT) – QUT is a leading research institution for translational health and medical research, driving innovation that directly enhances clinical practice and improves patient outcomes. The university maintains strong partnerships across extensive clinical networks, with many clinician researchers holding joint appointments at QUT and Brisbane’s major hospitals. Through the integration of diverse disciplinary expertise, our clinician researchers co-design effective and innovative solutions that deliver meaningful improvements in healthcare and shape the future of high-quality patient care.

Aligned with QUT’s commitment to real-world impact, the university provides comprehensive support for early phase and translational research, offering specialised infrastructure, expert research capability, and guidance on regulatory requirements. QUT’s advanced laboratory facilities, including biomedical engineering, genomics, and microbiome research laboratories, work seamlessly with industry and clinical partners to address contemporary health challenges, strengthen research translation, and deliver impactful, patient-centred outcomes.

Key areas: Nursing, Optometry, Palliative Care, Respiratory, Psychology, Immunology & Infection Control, Genomics, Biomedical Engineering, Medical Devices, Food & Supplements

Phase/s: Pre-clinical, Phase II, Phase III, Phase IV.



RDC Clinical

RDC Clinical – RDC Clinical is your partner in turning health and wellness innovations into proven products. Based in Brisbane, we specialise in evidence-based trials for complementary medicines, supplements, functional foods, and cosmetics. From study design and ethics approval to trial conduct, analysis, and reporting, we manage the entire process with precision and care. Our expert team delivers credible, regulatory-ready data to back your product’s safety and efficacy—helping you stand out in a competitive market. Passionate about science and human health, we transform ideas into trusted solutions that inspire consumer confidence and improve lives.

Key areas: Oncology; Cardiovascular; Respiratory; Neurology/Neurosciences; Endocrinology/Metabolic Disorders; Infectious Diseases; Immunology/Autoimmune; Gastroenterology; Hepatology; Dermatology; Psychiatry/ Mental Health; Pain Management; Women’s Health/ Reproductive Health; Pediatrics; Rare Diseases; Medical Devices; Digital Healthcare; Complementary medicines; Supplements; Functional foods; Cosmetics

Phase/s: Phase I; Phase II; Phase III; Phase IV



Regional Research Institute

Regional Research Institute – We provide local access to clinical trials and innovative therapies, enabling patients to participate in research closer to home while receiving care aligned with national and international standards.

RRI partners with study sponsors, investigators, clinical trial sites, and participants to support the efficient and ethical delivery of clinical trials. Through these collaborations, we accelerate research, expand access to novel treatments, and contribute to improved health outcomes for Australians.

By embedding research within regional communities, the Regional Research Institute is reshaping how and where clinical trials are delivered—bringing opportunities to the people who need them most.

Key areas: Cardiovascular, Endocrinology/Metabolic Disorders, Women’s Health, Medical Devices

Phase/s: Phase I; Phase II; Phase III; Phase IV



South Coast Renal

South Coast Renal – South Coast Renal Clinical Trial Unit is a private specialist nephrology and renal research site located on the Gold Coast, Queensland. Operating within South Coast Renal – Queensland’s largest private nephrology practice – SCR offers Phase I–III clinical trial capabilities across nephrology, immunology, and cardiovascular disease. The site provides dedicated GCP-compliant coordination, AI-assisted patient identification through Gentu EMR, partner pharmacy with cold-chain IP management, and experienced Principal Investigators with active trial portfolios. SCRCU supports both local and international sponsors seeking high-performing Australian sites with strong recruitment, established governance infrastructure, and a proven track record across multiple concurrent commercial studies.

Key areas: Renal, Cardiovascular, Endocrinology/Metabolic Disorders, Immunology/Autoimmune, Rare Diseases

Phase/s: Phase I; Phase II; Phase III



Sunshine Coast University Private Hospital

Sunshine Coast University Private Hospital: State-of-the-art private facility operated by Ramsay Health Care, co-located within the rapidly growing Sunshine Coast Health Precinct in Birtinya. Positioned adjacent to the public Sunshine Coast University Hospital, SCUPH plays a key role in expanding access to clinical trials within Queensland’s private healthcare sector.

SCUPH actively supports commercially sponsored and investigator-initiated clinical trials, offering a highly collaborative environment supported by experienced clinicians, efficient site operations, and streamlined ethics and governance processes. The hospital is increasingly recognised as a preferred location for sponsors seeking high-quality clinical trial delivery outside metropolitan hubs.

Key areas: SCUPH is involved in clinical trials across a range of specialties, including: Oncology; Cardiology; Gastroenterology; Orthopaedics; General and colorectal surgery; and Endocrinology and metabolic disorders

Phase/s: Phase II; Phase III; Phase IV



Tasman Oncology Research

Tasman Oncology Research – is a leading provider of Oncology Clinical Trials on the Gold Coast. We partner with Australian and International Pharmaceutical, Biotechnology and CROs to make novel treatments available to our patients.

We have extensive onsite capabilities and access to external local vendors to provide trial support. We have experience in Phase Ia/b, II, and III trials. Tasman employs a highly experienced team of Investigators and Researchers who work diligently to foster collaboration and patient education. We are committed to providing eligible patients to ethically approved research and to maintain patient safety and data integrity to the highest standards.

Key areas: Oncology, Rheumatology

Phase/s: Phase I; Phase II; Phase III



Translational Research Institute

Translational Research Institute (TRI): Collaborative model bringing together researchers, clinicians, and industry partners from institutions such as The University of Queensland, Mater Research, Queensland University of Technology, and Queensland Health, fostering an environment conducive to innovative translational research.

TRI supports the full spectrum of translational research and early clinical trials, often serving as a bridge between laboratory breakthroughs and bedside care. TRI’s Clinical Research Facility (CRF) located on the Princess Alexandra Hospital (PAH) campus provides state-of-the-art specialist facilities, resources and expertise for investigator-led and commercially sponsored clinical trials.

The CRF is housed directly across from the TRI on Levels 4 and 5 of the PAH R Wing and is operated by Metro South Hospital and Health Service, with direct access to hospital facilities and emergency response teams.

Key Areas: Infectious Diseases; Immunology/Autoimmune; Oncology; Neurology/Neuroscience; and Inflammatory Diseases

Phase/s: Phase I; Phase II; Phase III; Phase IV



University of the Sunshine Coast Clinical Trials

University of the Sunshine Coast (UniSC) Clinical Trials: A university based multi-site clinical trial network across the Sunshine Coast, Moreton Bay, Brisbane, and beyond. Specialising in delivering high-quality and efficient studies, from first-in-human through to late phase trials, UniSC Clinical Trials combine priority with passion to ensure operational excellence and improve access to innovative research within their community.

Key areas: Oncology; Cardiovascular; Respiratory; Neurology/Neurosciences; Endocrinology/Metabolic Disorders; Infectious Diseases; Immunology/Autoimmune; Gastroenterology; Hepatology; Dermatology; Psychiatry/Mental Health; Pain Management; Women's Health/Reproductive Health; Medical Devices; Rare Diseases

Phase/s: Phase I; Phase II; Phase III; Phase IV



UQCCR (The University of Queensland Centre for Clinical Research)

UQCCR (The University of Queensland Centre for Clinical Research): Located at the Herston Health Precinct, UQCCR is a world-class translational research institute dedicated to advancing clinical innovation and improving patient outcomes. While co-located with major public health facilities such as the Royal Brisbane and Women's Hospital (RBWH), UQCCR operates as a standalone academic research centre, fostering independent and collaborative research at the interface of laboratory science and bedside care.

UQCCR supports both investigator-driven and industry-partnered clinical research, providing infrastructure, expertise, and regulatory support for early-phase and translational studies. With state-of-the-art laboratories, clinical trial spaces, imaging and biomarker platforms, and links to biobanking and genomics, UQCCR enables the seamless integration of basic science with clinical application.

Key areas: Neurology/Neuroscience, Oncology, Gastroenterology; Mental Health; Women's health/Reproductive Health; and Infectious Diseases.

Phase/s: Pre-clinical; Phase I; Phase II; Phase III; Phase IV



Veracity Clinical Research

Veracity Clinical Research: Dermatology clinical research company that conducts clinical research trials in the field of inflammatory skin conditions.

Veracity Clinical Research is actively involved in both investigator-initiated and industry-sponsored trials, contributing to the development of over 30 PBS-approved treatments. Their current and upcoming studies encompass a range of dermatological conditions, offering opportunities for patient participation in cutting-edge research.

Key areas: The Veracity team works to provide successful interventions for a range of dermatological conditions including acne, atopic dermatitis/eczema, chronic plaque psoriasis, hidradenitis suppurativa, superficial basal cell carcinoma, actinic keratosis and more.

Phase/s: Phase II; Phase III; Phase IV



Wesley Research Institute – Clinical Trials Centre

Wesley Research Institute (WRI) – Clinical Trials Centre: Leading not-for-profit clinical research organisation primarily based in Brisbane, dedicated to improving health outcomes through translational and patient-centered research.

Operating across four key sites—including The Wesley Hospital, St Andrew's War Memorial Hospital, Buderim Private Hospital, and St Stephen's Hospital Hervey Bay (regionally)—WRI delivers high-quality, ethically governed clinical trials in collaboration with hospital specialists, industry sponsors, and academic partners.

WRI's Clinical Trials Network enables sponsors to access a broad and diverse patient population across Brisbane's north, south, and central corridors. Its integrated model connects experienced clinicians, dedicated research staff, and private hospital infrastructure, supporting both multi-site trials and localized studies.

Key areas: Oncology; Neurology/Neuroscience; Cardiology; Respiratory; Endocrinology and Diabetes; Gastroenterology; Rheumatology and Autoimmune; Medical Device; Mental Health and Cognitive Disorders; Palliative Care and Quality-of-Life Studies

Phase/s: Phase I (via clinical partnerships); Phase II; Phase III; Phase IV



Queensland service provider directory

Accounting/Tax/Business advisory



Acclime

[Acclime](#) – Acclime Australia’s full capabilities include entity formation, tax and R&D incentive advisory, resident directors, core compliance and accountancy support, and CFO and registered office services. Our senior consultants are based in Brisbane, Melbourne, Sydney, and Adelaide, as well as San Francisco and the UK. As an Acclime Australia client, you’ll be supported with access to multilingual staff who can provide on-site and virtual assistance.



Boomerang Biopathways

[Boomerang Biopathways](#) – enables global BioPharma and MedTech companies to run fast, cost-effective clinical trials in Australia. Boomerang Biopathways provides expert support across regulatory strategy, R&D tax incentives, CRO and site selection, contracting, and ethics approvals. Their deep local networks and operational insight reduce risk, accelerate timelines, and deliver high-quality data. Boomerang Biopathways act as a trusted extension of your team to maximise the value of your Australian clinical program.



Deloitte

[Deloitte](#) – R&D Tax incentive services, investment attraction, grants, business and tax advisory services.



Gild Bioscience

[Gild Bioscience](#) – Gild Bioscience is a Queensland-based service provider, supporting companies operating in Australia’s life sciences industry. Gild Bioscience deliver an integrated suite of services including corporate governance, accounting, taxation, legal, and R&D tax incentives and grants advisory.



Intellect Labs

[Intellect Labs](#) – provides R&D tax advice, grant strategy, collaboration management, and strategic advisory services to organisations in the life sciences sector. Our core focus is supporting sustainability and growth by helping organisations secure government funding, foster strategic partnerships, and align operational strategies to deliver long-term value.



Prime Financial

[Prime Financial](#) – has over 20 years’ life science experience assisting clients in R&D tax incentives, valuations, and capital raising. Prime has been a trusted partner to over 400 Australian Biotech/MedTech companies as well as assisting over a 200 foreign Biotech/MedTech companies establish an Australian presence. Partner with Prime to maximize funding opportunities, optimise your tax incentives, and propel your success in the dynamic world of biotechnology and health sciences.



RSM Australia

[RSM Australia](#) – assist companies with setting up in Australia to conduct R&D activities in Australia. This includes the following; incorporating an Australian subsidiary, advising on appropriate tax structures, transfer pricing considerations, annual tax and business compliance with the ATO and ASIC, assistance with claiming the Australian R&D tax incentive.



VenturePro

[VenturePro](#) – a specialist in innovation partnerships and the development of investment cases for innovation programs, with 25+ years’ experience bridging private sector, government, and research relationships. Track record of securing >\$2.4 billion in funding for innovation infrastructure and programs in Australia.

Contract Development and Manufacturing (CDMO)



BASE

BASE – The BASE facility, at The University Of Queensland, is a global leader in mRNA research and manufacture. BASE help scientists develop new mRNA medicines. They have experience building mRNA for a wide range of clinical applications, and provide end-to-end research services to design, manufacture and test new mRNA medicines..



Patheon Pharma Services

Patheon Pharma Services – The Thermo Fisher Scientific site in Brisbane, Australia is a state of the art facility, specializing in clinical and commercial manufacturing, and single use biologics technology. This site specializes in GMP for clinical and commercial manufacturing, including clinical cGMP manufacturing for Phase I, II, & III. Additional capabilities include: In-house analytical capabilities, QC and QA; experience with all mammalian cell lines; fed-batch, perfusion and XD® processes; and Single-use technologies. cGMP capabilities include both upstream and downstream.



Q-Gen Cell Therapeutics

Q-Gen Cell Therapeutics – Q-Gen, one of Australia's largest cell manufacturers, uses advanced technologies to deliver high-quality products. Their skilled team provides exceptional customer service and technical support, offering tailored solutions. With specialist teams in manufacturing, quality control, supply chain, engineering, and regulatory compliance, Q-Gen support clinical trial projects.



Southern RNA

Southern RNA – an Australian CDMO specialising in mRNA manufacturing. Their service offerings encompass mRNA production, including GMP and pre-clinical manufacturing, analytical testing, method and process development as well as tech-transfer. With facilities in Brisbane and Gold Coast, Southern RNA provide scalable manufacturing solutions from research-grade to clinical grade, as well as supply proprietary mRNA capping technology and plasmid DNA production and testing services.

Clinical Research Organisations (CROs)



Agilex Biolabs

Agilex Biolabs – Agilex Biolabs is Australia's leading CRO, specializing in bioanalytical and toxicology services for pharmaceutical and biotech companies. With over 25 years of experience, they offer LC-MS/MS and immunoassay bioanalysis, biomarker and immunobiology assays, and GLP-compliant toxicology studies, supported by advanced technology and global accreditations.



Alithia Life Sciences

Alithia Life Sciences – Alithia Life Sciences is an Australian owned boutique, full-service capability Contract Research Organization (CRO) launched to support and assist pharmaceutical, biotechnology, device companies and institutional research groups undertaking their project in the Australian region and beyond. They have an average of 15-20+ years of operational expertise and industry experience in various therapeutic areas including, first in human studies (FIH), devices, endocrinology, oncology, neurology, gastroenterology, rare and pediatric diseases and vaccines. Our breadth of expertise in the academic, commercial and biotechnology settings can support your project from Phase I through to Phase III.



Beyond Drug Development

[Beyond Drug Development](#) – an Australian company specializing in providing strategic support services for clinical research and trials. With expertise across clinical operations, ethics submissions, governance, and project management, the company helps clients navigate the complexities of conducting trials in Australia and New Zealand. Beyond Drug Development focuses on accelerating trial start-up and ensuring compliance, making it a key partner for sponsors, CROs, and research organizations aiming for efficient, high-quality trial execution.



biostate

Biostate

[Biostate](#) – An active participant in the Australian clinical trials sector providing independent Resident Director services for Australian subsidiaries of international companies, consulting services and investment and clinical trial sponsorship services through wholly owned subsidiary Gondwana Trials Pty Ltd.



Boomerang Biopathways

[Boomerang Biopathways](#) – enables global BioPharma and MedTech companies to run fast, cost-effective clinical trials in Australia. Boomerang Biopathways provides expert support across regulatory strategy, R&D tax incentives, CRO and site selection, contracting, and ethics approvals. Their deep local networks and operational insight reduce risk, accelerate timelines, and deliver high-quality data. Boomerang Biopathways act as a trusted extension of your team to maximise the value of your Australian clinical program.



CROW Clinical

[CROW Clinical](#) – full service and tailorable Clinical Research Organization servicing Australia and New Zealand. CROW are the only CRO that offers a dedicated team of Field Clinical Engineers, specializing in high tech medical device start-ups. CROW Clinical pride themselves on tailoring a specific service, so you only pay for exactly what you need. CROW is a premier Clinical Research Organization without the huge price tag.



Gallipoli Medical Research

[Gallipoli Medical Research](#) – a leading Brisbane institute translating research into practical tools for better health. GMR focus on the biopsychosocial impacts of military service, co-designed with veterans. They run liver, respiratory and oncology trials with top clinicians. Gallipoli's Translation Unit helps turn evidence into action, offering veteran engagement, health economics, and service evaluation to maximise real-world impact.



IQVIA

[IQVIA](#) – full-service CRO. IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Leveraging a robust suite of real-world data, AI-driven insights, and operational expertise, IQVIA supports end-to-end clinical trial delivery across all phases and therapeutic areas, helping clients accelerate drug development and improve patient outcomes.



My Medical Department

[My Medical Department](#) – a physician-led medical consultancy, bringing excellence to the development and use of your products throughout their lifecycle. Their versatile team offers a range of solutions, tailored to your organisation's specific requirements. My Medical Department cater services from clinical operations, clinical development, medical writing, pharmacovigilance, medical monitoring, quality and regulatory, code compliance and sign-off, and medical information.



Novotech

Novotech – a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development. With deep therapeutic and regulatory expertise and an expansive global footprint across the Asia-Pacific region, North America, and Europe, Novotech offers clients an accelerated path to bring life-changing therapies to market.



Nucleus Network

Nucleus Network – leading Australian clinical research organisation (CRO) specialising in Phase I clinical trials, with purpose-built facilities in Melbourne, Brisbane, and Minneapolis (USA). As one of the few CROs globally with operations in both the Southern and Northern Hemispheres, Nucleus Network provides year-round trial continuity for sponsors seeking accelerated timelines.

With a strong focus on first-in-human (FIH), early-phase, and healthy volunteer studies, Nucleus offers full-service capabilities, including protocol design, ethics and regulatory submission, clinical trial execution, bioanalytics, and data management. Their facilities are equipped with high-acuity units and advanced clinical pharmacology infrastructure, enabling complex and high-risk early-phase studies. Backed by experienced clinical teams and robust governance processes, Nucleus Network supports biopharma and biotech clients worldwide in rapidly translating preclinical assets into clinical development.



QCIF


QCIF – QCIF Ltd is a non-profit organisation supporting research excellence and innovation through advanced data and digital infrastructure solutions for academia, industry, and government across Australia. As part of the national research ecosystem, QCIF provides specialised expertise in biostatistics, bioinformatics, health informatics, applied AI, machine learning and data management.

QCIF's team of biostatisticians and data scientists offer end-to-end support for clinical trials and observational studies, ensuring methodological rigour and reproducibility. Capabilities include study design, data wrangling, visualisation, and statistical analysis, as well as assistance with grant applications to strengthen bids in attracting external funds.



Resolian Bioanalytics

Resolian Bioanalytics – Resolian Bioanalytics, with over 25 years of experience, is a global bioanalytical CRO specializing in regulated bioanalysis, DMPK, and GMP CMC services. Their 500+ experts across the US, UK, Australia, and China operate under harmonized SOPs and processes, enabling seamless method transfers between sites. They offer comprehensive capabilities including LC-MS/MS bioanalysis, PK immunoassays, immunogenicity, flow cytometry, biomarkers and cell-based assays in their GLP accredited facility to ensure the highest quality standards for regulated studies.



Sunrise Clinical

Sunrise Clinical – Sunrise Clinical is a boutique, founder-led clinical research organisation based on the Sunshine Coast, QLD.

They offer flexible, expert-led clinical research and business consulting services under two distinct business streams:

- Australian Local Sponsor Services
- Clinical Research Consultancy
- People and Culture Consultancy

With over 25 years of experience in clinical research and business management, they help clients navigate the complex Australian regulatory and clinical landscape with operational excellence and people-focused support.



Thompson Brain and Mind Healthcare

Thompson Brain and Mind Healthcare – Thompson Brain & Mind Healthcare (TBMH) is an Australian not-for-profit mental health and neuroscience organisation delivering precision-based clinical services, clinical trials, and translational research. Based on the Sunshine Coast, Queensland, TBMH integrates psychiatry, psychology, neurotechnology, pharmacogenomics, neuroimaging, and neuromodulation within a multidisciplinary model of care. The organisation operates advanced clinical trials capabilities across psychiatric and neurological conditions, including treatment-resistant depression, PTSD, anxiety disorders, and neurodevelopmental conditions. TBMH has expertise in psychedelic-assisted therapies, ketamine treatments, TMS, QEEG, and biomarker-driven approaches, with a strong focus on innovation, real-world data, and scalable translational neuroscience infrastructure.

Funding/ Venture Capital



OneVentures

[OneVentures](#) – OneVentures – a leading Australian venture capital firm providing capital and strategic support to high-growth companies. Through its healthcare funds, OneVentures invests in innovative biomedical businesses to drive assets through key value-inflection milestones across clinical development, validation, regulatory progress, and commercialisation. The firm works closely with founders and management teams to accelerate growth, support clinical development pathways, and connect companies with global expertise, partners, and investors. With strong sector experience and a track record in healthcare investing, the team has deep domain expertise and experience in commercialising biomedical companies from founding to IPO. OneVentures has a presence across Queensland, New South Wales, and Victoria.



Tenmile

[Tenmile](#) – Tenmile is a specialist health technology investor with themes spanning oncology, AMR, mental health, women's health, metabolic disease, technologies rewriting drug discovery and beyond. They find unmet needs where the science is ready, there's commercial opportunity and capital hasn't arrived. With scientific conviction and dependable capital, they back bold ideas before inflection points and help them on their journey to help changing lives.

Human Research Ethics Committees (HRECs)



Bellberry Limited

[Bellberry Limited](#) – a national, private not-for-profit organisation providing streamlined scientific and ethical review of human research projects across Australia. Established in 2004, Bellberry operates 12 NHMRC-certified Human Research Ethics Committees (HRECs), offering efficient, independent ethics reviews for clinical drug trials, social science, and observational studies. Utilising an online submission system called eProtocol, Bellberry ensures timely reviews, with the capability to hold up to 13 HREC meetings per month. Any surplus funds generated are reinvested into the Australian medical research community.



Ethicsready

[Ethicsready](#) – Ethicsready has been developed to provide Sponsors, Contract Research Organisations (CRO), Clinical Trial Sites and Investigators with practical guidance, document content development and Human Research Ethics Committee (HREC) submission preparation and/or submission services.

Insurance



Avatar Brokers

[Avatar Brokers](#) – Specialist life science & technology broker, trading since 2002. Deep expertise with clinical trial placements - from early stage through to large, complex, global Phase 3 programs. Broker to & sponsor of Life Sciences Queensland, BioMelbourne Network & AusBiotech.

Legal/ Intellectual Property (IP)

DENTONS

Dentons Australia

[Dentons Australia](#) – provides legal and advisory solutions through its expert lawyers in the large health care practice. Dentons lawyers have deep work experience with organisations engaged in the design, development, delivery and commercialisation of research activities. Their lawyers help clients strengthen compliance and fortify plans for minimising risks associated with carrying out clinical research projects.



FB Rice

[FB Rice](#) – As market leaders, FB Rice respond to your IP needs with the right technical expert every time. Their award-winning firm comprises IP specialists from a wide range of technologies and industries including Biotechnology, Chemistry, Engineering, Medical Technology, Computer and Electrical Sciences. FB Rice thrive on their ability to solve problems and give practical advice by combining outstanding intellectual capability, creativity and commercial insight.

MinterEllison.

MinterEllison

[MinterEllison](#) – MinterEllison is Australia's leading independent law firm, with specialist expertise supporting medical research, development and clinical trials. Our market-leading, Band 1 Chambers-ranked life sciences team advises sponsors, CROs, investigators, HRECs and research institutions across the full trial lifecycle. We deliver integrated advice across clinical trial regulation and agreements, governance, intellectual property, privacy and data, funding, commercialisation and supply arrangements, workforce, insurance and disputes in high-stakes research environments.

gadens

Gadens

[Gadens](#) – leading Australian law firm that offers specialized legal services for clinical trials, supporting sponsors, research institutions, and healthcare providers. Their expertise includes drafting and negotiating clinical trial agreements, advising on regulatory compliance with the Therapeutic Goods Administration (TGA) requirements, navigating ethics and governance frameworks, and managing intellectual property and data protection issues. Gadens ensures that clinical trials in Australia are conducted with strong legal foundations, helping clients mitigate risk and meet ethical and legal obligations.



McCullough Robertson

[McCullough Robertson](#) – prominent Australian law firm that provides tailored legal services for clinical trials across the healthcare and life sciences sectors. Their support includes advising on regulatory compliance, preparing and reviewing clinical trial agreements, managing ethics and governance processes, and addressing privacy, data protection, and intellectual property concerns. With deep industry knowledge and experience, McCullough Robertson helps sponsors, CROs, and research organizations navigate the complex legal landscape of clinical trials in Australia efficiently and compliantly.

SPRUSON & FERGUSON

Spruson & Ferguson

[Spruson & Ferguson](#) – International biomedical and pharmaceutical companies looking to the APAC region face a range of challenges: securing strong patent protection across jurisdictions with differing requirements, extending patent term on pharmaceuticals, enforcing rights across diverse jurisdictions, and navigating commercial and research agreements. Clinical trials add a further layer of complexity.

Spruson & Ferguson is uniquely placed to meet these needs. As one of the region's most experienced and award-winning IP firms, they provide integrated services across the full spectrum of intellectual property - offering streamlined IP services in over 25 jurisdictions from 10 offices across Australia, Southeast Asia and China. Their team in Australia brings together a large team of highly skilled patent and trade mark attorneys alongside specialist IP lawyers working in litigation, disputes, commercialisation and data protection.

With deep sector expertise and broad regional reach, they deliver trusted IP strategies that enable biomedical and pharmaceutical companies to innovate and grow with confidence.



Thomson Geer Lawyers

[Thomson Geer Lawyers](#) – has an in-depth understanding of the life sciences and health sector in Australia and globally. Services include advising in relation to research and clinical trial arrangements and agreements (for medicines and devices). Thomson Geer Lawyers also assist with privacy and regulatory advice, intellectual property protection and licensing, material transfer agreements, distribution, supply and manufacturing agreements and purchase and sale of product lines.

Logistics

cencora

World Courier

Worldwide Courier (Aust)

[Worldwide Courier \(Aust\)](#) – part of [Cencora](#), provides specialty logistics services to drive the clinical and commercial success of our partners around the globe.

World Courier deliver peace of mind through world-class supply chain programs, transport services, decentralized clinical trial support, and storage for time- and temperature-sensitive products, including innovative medicines like cell and gene therapies.

R&D Financing/Financing Options



Endpoints Capital

[Endpoints Capital](#) – Australian R&D finance company specializing in funding innovation for life science companies utilizing the Australian R&D tax incentive scheme. Endpoints Capital understand the life sciences ecosystem and the challenges, including financing that biotechnology companies face getting their treatment or device into the clinic. Endpoints Capital are excited by the opportunity to help biotechs accelerate their discovery of new medicines, therapies and life changing treatments.



Radium Capital

[Radium Capital](#) – is Australia's leading provider of R&D finance, empowering biotech, medtech and health innovators to launch, scale and commercialise faster. Since 2017, Radium Capital has deployed \$1 billion in non-dilutive funding to over 1,000 companies. Radium Advances provide early access to the R&D Tax Incentive refund, helping businesses smooth cash flow, reinvest in R&D and growth, attract additional funding and reduce capital outlay. Designed to complement other forms of capital, Advances can be one-off injections or used strategically throughout the year. Radium partners with innovators to move ideas to impact by providing capital, connections and trusted advice.

Regulatory



Beyond Drug Development

Beyond Drug Development – an Australian company specializing in providing strategic support services for clinical research and trials. With expertise across clinical operations, ethics submissions, governance, and project management, the company helps clients navigate the complexities of conducting trials in Australia and New Zealand. Beyond Drug Development focuses on accelerating trial start-up and ensuring compliance, making it a key partner for sponsors, CROs, and research organizations aiming for efficient, high-quality trial execution.



Graythan Regulatory Services

Graythan Regulatory Services – have a strong track record of successful submissions, registrations, and developing pharmaceutical drugs globally. Graythan offer Regulatory Affair support, Product Development, Vendor /Program Management, Medical Writing and Gene Therapy Application/IBC services.



My Medical Department

My Medical Department – a physician-led medical consultancy, bringing excellence to the development and use of your products throughout their lifecycle. Their versatile team offers a range of solutions, tailored to your organisation's specific requirements. My Medical Department cater services from clinical operations, clinical development, medical writing, pharmacovigilance, medical monitoring, quality and regulatory, code compliance and sign-off, and medical information.

SCENDEA

Scendea

Scendea – an international product development and regulatory consulting group. Scendea's expert team offers strategic and operational support in the fields of Nonclinical, CMC, Clinical, and Regulatory to successfully guide medicinal products from early development to marketing approval. Their scientific excellence, industry experience, and collaborative approach enable their clients to deliver high-quality innovative solutions aligned with jurisdiction-specific regulatory requirements.

Recruitment/Talent



KE Select

KE Select – an Australian based, leading Scientific & Medical Technology Recruitment Partner for many organisations within the Life Science, Medical, Clinical, Pharmaceutical, Hospital and Healthcare space. KE Select carries out Executive searches, permanent and Contract-based recruitment projects within the STEM sector. They have built a strong, extensive network of talent in the clinical trials industry enabling them to support their clients in finding the right talent.



mexec

mexec - Executive Search – mexec 'connects people for success' - mexec are experienced in resourcing staff for companies including board, executive search and selection services to build your leadership team. mexec specialise in the biotechnology, health and innovation sectors. They offer comprehensive services for individuals including our mexec jobstrategy™ program, and interview coaching. mexec works at all levels to CEO and board.



TranZition Group

TranZition Group – Why TranZition? TranZition's Vision is to help the Biotechnology Industry grow and prosper by recruiting suitably experienced, empathic, enthusiastic, and supportive people into similarly aligned companies. Can and have assisted with all C-suite/Clinical Trials Managers, CRA's, QA and Regulatory roles. Plus, many more!

Tools and Enabling Technology



AGRF

[AGRF](#) – AGRF is Australia’s leading provider of high-quality multi-omic services, committed to quality, innovation, and collaboration. Through their national network, AGRF provides access to clinically accredited (NATA ISO 15189), cutting-edge technologies that support discovery and applications to biomedical research, clinical trials, and clinical genomic testing. They offer a range of services from single-gene analysis, gene panels and whole genome sequencing, to proteomic biomarker discovery. Their comprehensive suite of multi-omic services is supported by advanced bioinformatics and customisable data delivery. AGRF partners with academia, healthcare, and industry to power research, enable innovation, and drive real-world impact.



ARM Hub

[ARM Hub](#) – ARM Hub is a not-for-profit, Australian Government-backed AI Adopt Centre supporting biotech research excellence and commercialisation through advanced data infrastructure, applied AI, and clinical trial enablement for sponsors conducting trials in Australia. ARM Hub’s Data and AI as a Service provides secure, scalable platforms for clinical research, including a agnostic AI Lakehouse that ingests and standardises multi-format, multi-language clinical data across distributed trial sites with regulatory-grade audit trails aligned to HIPAA, CDISC, and GxP for FDA 510(k), CE Mark, and TGA submissions.

ARM Hub’s expertise spans biostatistics, bioinformatics, health informatics, applied AI, machine learning, and data engineering, enabling robust study design, advanced data analysis, and reproducible workflows. Through co-designed Data and AI Roadmaps, tailored training, and advisory services, ARM Hub helps biotech sponsors build analytical capability and accelerate global market entry without surrendering equity or intellectual property.



Clinials

[Clinials](#) – AI-driven healthtech platform that simplifies clinical trial documentation, making complex protocols accessible and actionable for sponsors, CROs, and sites. Embed Clinials’ AI-generated plain language summaries, protocol overviews, patient information sheets and multilingual content into best practice templates.



Datarwe

[Datarwe](#) – a Queensland-based analytics company delivering AI-driven data services for healthcare. By focusing on low-resource interventions, they empower providers with data-driven insights to enhance patient outcomes and reduce costs. Their platform harnesses real-time clinical data to identify trends and support critical decisions. Through collaboration with healthcare partners, Datarwe transforms cutting-edge technology into practical patient care improvements.



Foxo

[Foxo](#) – is revolutionising clinical trial delivery. Designed for modern multi-site trial environments, Foxo enables QR-enabled patient messaging through Foxo Patient Connect, allowing participants to securely live engage with rich media for adverse events, ask questions, or reschedule visits without needing to download an app. Foxo’s Powerlist supports dynamic participant recruitment by allowing investigators to flag candidates and coordinators to triage them collaboratively, creating real-time visibility for sponsor teams. Foxo’s smart data tools, including AI-powered summarisation, provide live insights into case discussions and enable transparent, two-way communication with sponsors - eliminating manual documentation and disconnected workflows.



Gallipoli Medical Research

[Gallipoli Medical Research](#) – a leading Brisbane institute translating research into practical tools for better health. GMR focus on the biopsychosocial impacts of military service, co-designed with veterans. They run liver, respiratory and oncology trials with top clinicians. Gallipoli's Translation Unit helps turn evidence into action, offering veteran engagement, health economics, and service evaluation to maximise real-world impact.



Gelomics

[Gelomics](#) – revolutionizing drug development by enabling the growth of human tissue models in vitro, providing an ethical, cost-effective, and predictive alternative to animal testing.



Health Translation Queensland

[Health Translation Queensland \(HTQ\)](#) is a comprehensive and accessible online resource that aims to actively support researchers and clinical trial teams throughout the clinical trials process. HTQ aims to empower the next generation of researchers with the knowledge and skills they need to conduct high-quality clinical trials, support scientific discovery and medical advancement, and ultimately improve patient outcomes.

[HTQ Clinical Trials Hub](#) – the Hub provides access to top resources and helpful information from across the web in one central location and includes a range of useful blogs developed in consultation with some of Queensland's top clinical trial experts.



QCIF

[QCIF](#) – QCIF Ltd is a non-profit organisation supporting research excellence through advanced data infrastructure and enabling technologies for academia, industry, and government across Australia. QCIF provides secure, scalable tools for clinical research, including support for REDCap, a widely used platform for building and managing webbased data collection forms as well as an ISO27001 standard Secure/Trusted Research Environment in KeyPoint to handle analysis of sensitive patient data.

In addition to infrastructure, QCIF offers expertise in biostatistics, bioinformatics, health informatics, applied AI, machine learning and data management, supporting robust study design, data analysis, and reproducible workflows. Training is available across key tools and methods, helping to build R&D capability and ensure methodological rigour throughout the research lifecycle.



Southern RNA

[Southern RNA](#) – an Australian CDMO specialising in mRNA manufacturing. Their service offerings encompass mRNA production, including GMP and pre-clinical manufacturing, analytical testing, method and process development as well as tech-transfer.

With facilities in Brisbane and Gold Coast, Southern RNA provide scalable manufacturing solutions from research-grade to clinical grade, as well as supply proprietary mRNA capping technology and plasmid DNA production and testing services.



Vaxxas

Vaxxas is enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP) targeting applications in infectious diseases and oncology. Vaxxas' needle-free technology is a small patch including thousands of microprojections, each coated with a small dose of vaccine. When applied to the skin, the patch delivers the vaccine directly to the immune cells below the surface, prompting an immune response comparable to needle and syringe delivery with less vaccine.

Vaccine delivery via Vaxxas' HD-MAP technology has the potential to overcome challenges faced by traditional delivery of vaccines (such as cold-chain storage). HD-MAP vaccines are also designed to be easier to administer, with the potential for self-administration in future pandemic responses. They are also less invasive and more patient-friendly than traditional needle-based injection.



Xemosoft

Xemosoft – Phoenix is a cloud-based clinical trials pharmacy management platform built by pharmacists and developers. Fully compliant with FDA 21 CFR Part 11 and ICH GCP, it gives pharmacists one workspace to set up trials via reusable drug templates, manage inventory across blinded and open arms, dispense with auto-printed labels, and automate Master, Subject and Destruction accountability logs. Every action is captured in a complete audit trail, and Monitors verify logs remotely via secure checkbox signoff – no more manual signing. Multi-site management and auto-calculated fees eliminate hours of admin, keeping records audit-ready and freeing pharmacists to focus on trial delivery.

Toxicology/Analytics



360biolabs

360biolabs – Australia's most comprehensive bioanalytical laboratory providing a single laboratory for all of your clinical trial requirements. They support pharmacokinetic (PK) analysis (large molecule, small molecules, peptides, proteins, ATMPs and vaccines), a diverse range of pharmacodynamic (PD) endpoints (including flow cytometry, biomarkers, molecular assays, immunogenicity, virology and central lab services, in a quality assured environment (GLP, GCP, ISO / IEC 17025).



Agilex Biolabs

Agilex Biolabs – Agilex Biolabs is Australia's leading CRO, specializing in bioanalytical and toxicology services for pharmaceutical and biotech companies. With over 25 years of experience, they offer LC-MS/MS and immunoassay bioanalysis, biomarker and immunobiology assays, and GLP-compliant toxicology studies, supported by advanced technology and global accreditations.



QCIF

QCIF – QCIF Ltd is a non-profit organisation supporting research excellence through advanced analytics, data infrastructure, and enabling technologies for academia, industry, and government across Australia. QCIF provides secure, scalable tools for clinical research, including support and training for REDCap, a widely used platform for managing web-based data collection. In addition, QCIF has a ISO27001 standard Secure/Trusted Research Environment in KeyPoint to handle analysis of sensitive patient data.

QCIF's expertise spans biostatistics, bioinformatics, health informatics, applied AI, machine learning and data management, enabling robust study design, advanced data analysis, and reproducible workflows. Through tailored training and advisory services, QCIF helps to build analytical capability and apply cutting-edge methods across the clinical research lifecycle.



Resolian Bioanalytics

Resolian Bioanalytics – Resolian Bioanalytics, with over 25 years of experience, is a global bioanalytical CRO specializing in regulated bioanalysis, DMPK, and GMP CMC services. Their 500+ experts across the US, UK, Australia, and China operate under harmonized SOPs and processes, enabling seamless method transfers between sites. They offer comprehensive capabilities including LC-MS/MS bioanalysis, PK immunoassays, immunogenicity, flow cytometry, biomarkers and cell-based assays in their GLP accredited facility to ensure the highest quality standards for regulated studies.



Scientific Services – QIMR Berghofer

Scientific Services – QIMR Berghofer provides integrated services that drive world-class research programs forward. These services are now available to external clients, extending their expertise beyond our Institution’s walls. QIMR Berghofer specialists will consult with you to meet your clinical trial needs, so you can focus on your goals. Services: Sample Processing, Histology*, Microscopy, Flow Cytometry*, Sequencing, Metabolomics, Proteomics, PC3, Animal Facility. (* have ISO 17025 accreditation).

Training



Clueo Clinical

Clueo Clinical – offers industry-aligned training and talent development programs that upskill STEM and health professionals into job-ready clinical research staff. Clueo support sponsors, CROs, and sites by providing tailored onboarding, clinical operations staff training including CRA/CRC/CTA/SSU, and workforce solutions to meet the evolving demands of clinical trials across Australia.





📍 Brisbane, Queensland

Queensland industry support

Queensland’s biomedical and clinical trials ecosystem is underpinned by a highly collaborative network of state agencies and industry partners working in lockstep to accelerate innovation, attract global investment, and deliver world-class research outcomes.

Trade and Investment Queensland (TIQ), Queensland Health (QH), the Department of State Development, Infrastructure and Planning (DSDIP), the Department of Environment, Science and Innovation (DESI), and industry body Life Sciences Queensland (LSQ) each play a distinct but complementary role—supporting everything from investment facilitation and clinical trial delivery to research commercialisation and sector-wide advocacy.

Together, we form a coordinated and responsive support system that enables Queensland to thrive as a globally competitive location for life sciences and clinical research.

Trade and Investment Queensland

[Trade and Investment Queensland \(TIQ\)](#) – the Queensland Government’s global business agency, helping international investors and partners connect with Queensland’s world-class life sciences sector. TIQ plays a central role in attracting investment, facilitating clinical trials partnerships, and promoting Queensland innovation at international platforms.

Queensland Health

[Queensland Health \(QH\)](#) – provides statewide coordination of public hospitals, health services, and research infrastructure, making it a key partner in the delivery of high-quality clinical trials. Through its Health Service Evaluation, Research and Translation Branch and Hospital and Health Services (HHSs), QH enables access to large patient populations, trial-ready sites, and skilled healthcare professionals.

Department of State Development, Infrastructure and Planning

[Department of State Development, Infrastructure and Planning \(DSDIP\)](#) – supports the growth of Queensland’s biomedical and biomanufacturing sectors through strategic infrastructure planning, industry development programs, and investment facilitation. The department plays a leading role in major project support and the development of innovation precincts and industrial hubs.

Department of Environment, Tourism, Science and Innovation

[Department of Environment, Tourism, Science and Innovation \(DETSI\)](#) – drives Queensland’s research, innovation, and science agenda, including targeted support for health and biomedical research. The department funds research collaboration, commercialisation pathways, and programs that build Queensland’s innovation capacity across life sciences and clinical trials.

Life Sciences Queensland

[Life Sciences Queensland \(LSQ\)](#) – the peak industry body representing Queensland’s life sciences sector. It plays a critical convening role between government, research, and industry—advocating for growth, supporting startups and SMEs, and promoting Queensland’s capabilities in biopharma, medtech, and clinical research globally.

Queensland’s biomedical growth is backed not only by state and national support—but also by proactive local governments that champion innovation, investment, and clinical research, such as:

Brisbane Economic Development Agency

[Brisbane Economic Development Agency \(BEDA\)](#) plays a key role in driving the growth of Brisbane’s biomedical and clinical trials sector. As the city’s lead economic development agency, BEDA supports industry investment, promotes partnerships with research institutions and hospitals, and works to attract global health and medtech companies to Brisbane’s innovation ecosystem—including the world-class facilities at the Translational Research Institute and the Princess Alexandra Hospital precinct.



Queensland service provider index

| | | | |
|--|----------|---|-----------|
| Key regulator and schemes | 4 | Sunshine Coast University Hospital (SCUH) | 11 |
| Clinical Trial Approval (CTA) Scheme | 4 | Sunshine Coast University Private Hospital | 21 |
| Clinical Trial Notification (CTN) Scheme | 4 | Tasman Oncology Research | 21 |
| Therapeutic Goods Administration | 4 | The Prince Charles Hospital (TPCH) | 13 |
| Funding at a glance in Australia | 5 | Townsville University Hospital (TUH) | 11 |
| Sources of funding | 5 | UQCCR (The University of Queensland Centre for Clinical Research) | 22 |
| Private capital funding in Australia | 5 | Veracity Clinical Research | 22 |
| Brain and Mind Hub | 16 | Wesley Research Institute – Clinical Trials Centre | 22 |
| Cairns Hospital | 12 | Accounting/Tax/Business advisory | 24 |
| Coral Sea Clinical Research Institute | 16 | Acclime | 24 |
| Gallipoli Medical Research Clinical Trials Unit | 16 | Boomerang Biopathways | 24 |
| Gold Coast University Hospital (GCUH) | 10 | Deloitte | 24 |
| Griffith University Clinical Trial Unit | 16 | Gild Bioscience | 24 |
| Healthscope | 17 | Intellect Labs | 24 |
| Icon Group | 17 | Prime Financial | 24 |
| Ipswich Hospital | 14 | RSM Australia | 24 |
| James Cook University Clinical Trials | 17 | VenturePro | 24 |
| John Flynn Private Hospital | 17 | Contract Development and Manufacturing (CDMO) | 25 |
| Logan Hospital | 13 | BASE | 25 |
| Mackay Base Hospital | 12 | Patheon Pharma Services | 25 |
| Mater Research | 18 | Q-Gen Cell Therapeutics | 25 |
| Nucleus Network – Brisbane | 18 | Southern RNA | 25 |
| Paratus Clinical | 18 | Clinical Research Organisations (CROs) | 25 |
| Pindara Private Hospital | 18 | Agilex Biolabs | 25 |
| Princess Alexandra Hospital (PAH) | 9 | Alithia Life Sciences | 25 |
| Q-Gen Cell Therapeutics | 19 | Beyond Drug Development | 26 |
| QIMR Berghofer Medical Research Institute – Clinical Trials and Research | 19 | Biostate | 26 |
| Queen Elizabeth II Jubilee Hospital (QEII) | 15 | Boomerang Biopathways | 26 |
| Queensland Children’s Hospital (QCH) | 10 | CROW Clinical | 26 |
| Queensland Eye Institute | 19 | Gallipoli Medical Research | 26 |
| Queensland University of Technology (QUT) | 20 | IQVIA | 26 |
| RDC Clinical | 20 | My Medical Department | 26 |
| Redcliffe Hospital and Caboolture Hospital | 14 | Novotech | 27 |
| Regional Research Institute | 20 | | |
| Royal Brisbane and Women’s Hospital (RBWH) | 9 | | |
| Scientific Services and Core Facilities | 19 | | |
| South Coast Renal | 21 | | |

| | | | |
|---|-----------|--------------------------------------|-----------|
| Nucleus Network | 27 | Beyond Drug Development | 31 |
| QCIF | 27 | Graythan Regulatory Services | 31 |
| Resolian Bioanalytics | 27 | My Medical Department | 31 |
| Sunrise Clinical | 27 | Scendea | 31 |
| Thompson Brain and Mind Healthcare | 27 | | |
| Funding/Venture Capital | 28 | Recruitment/Talent | 31 |
| OneVentures | 28 | KE Select | 31 |
| Tenmile | 28 | mexec | 31 |
| | | TranZition Group | 31 |
| Human Research Ethics Committees (HRECs) | 28 | Tools and Enabling Technology | 32 |
| Bellberry Limited | 28 | AGRF | 32 |
| Ethicsready | 28 | Clinicals | 32 |
| | | Datarwe | 32 |
| Insurance | 28 | Foxo | 32 |
| Avatar Brokers | 28 | Gallipoli Medical Research | 33 |
| | | Gelomics | 33 |
| Legal/Intellectual Property (IP) | 29 | Health Translation Queensland | 33 |
| Dentons Australia | 29 | QCIF | 33 |
| FB Rice | 29 | Southern RNA | 33 |
| Gadens | 29 | Vaxxas | 34 |
| McCullough Robertson | 29 | Xemosoft | 34 |
| MinterEllison | 29 | | |
| Spruson & Ferguson | 30 | Toxicology/Analytics | 34 |
| Thomson Geer Lawyers | 30 | 360biolabs | 34 |
| | | Agilex Biolabs | 34 |
| Logistics | 30 | QCIF | 34 |
| Worldwide Courier (Aust) | 30 | Resolian Bioanalytics | 35 |
| | | Scientific Services – QIMR Berghofer | 35 |
| R&D Financing/Financing Options | 30 | Training | 35 |
| Endpoints Capital | 30 | Clueo Clinical | 35 |
| Radium Capital | 30 | | |
| Regulatory | 31 | | |

References and resources

AIATSIS Code of Ethics for Aboriginal and Torres Strait Islander Research

<https://aiatsis.gov.au/sites/default/files/2020-10/aiatsis-code-ethics.pdf>

Australian-Business-Guide-to-Implementing-the-UN-Declaration-on-the-Rights-of-Indigenous-People_FINAL.pdf

[Australian-Business-Guide-to-Implementing-the-UN-Declaration-on-the-Rights-of-Indigenous-People_FINAL.pdf](https://www.australianclinicaltrials.gov.au/sites/default/files/2020-10/Australian-Business-Guide-to-Implementing-the-UN-Declaration-on-the-Rights-of-Indigenous-People_FINAL.pdf)

Australian clinical trial handbook | Therapeutic Goods Administration (TGA)

<https://www.tga.gov.au/resources/guidance/australian-clinical-trial-handbook>

ACTA – Australian Clinical Trials Alliance – Better health through best evidence

<https://clinicaltrialsalliance.org.au/>

ANZCTR - Australia and New Zealand Clinical Trials Registry

<https://anzctr.org.au/>

National One Stop Shop for health and medical research | Australian Clinical Trials

<https://www.australianclinicaltrials.gov.au/national-reforms/national-one-stop-shop-health-and-medical-research>

Clin Trial Refer – ClinTrial Refer App connects doctors & patients to recruiting clinical trials.

<https://www.clintrialrefer.org.au/>

ClinicalTrials.gov

<https://clinicaltrials.gov/>

Clinical Trials Queensland

<https://clinicaltrialsqld.com/>

Clinical trials | Therapeutic Goods Administration (TGA)

<https://www.tga.gov.au/products/unapproved-therapeutic-goods/clinical-trials>

DoRA 2.0 | Database of Research Activity

<https://dora.health.qld.gov.au/qldresearchjspui/>

Ethical guidelines for research with Aboriginal and Torres Strait Islander peoples | NHMRC

<https://www.nhmrc.gov.au/research-policy/ethics/ethical-guidelines-research-aboriginal-and-torres-strait-islander-peoples>

ICH_E6(R3)_Step4_FinalGuideline_2025_0106.pdf

https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf

My Clinical Trial Planner | Clinical Trials Hub

<https://clinicaltrialshub.htq.org.au/clinical-trial-planner/>

NHMRC – National Statement on Ethical Conduct in Human Research 2023

<https://www.nhmrc.gov.au/about-us/publications/national-statement-ethical-conduct-human-research-2023>

National Statement on Ethical Conduct in Human Research 2023 | NHMRC

<https://clinicaltrialsqld.com/sites/default/files/2025-01/CTSAP%20Report%20Card%20September%202024%20Final.pdf>

Queensland public hospitals health and medical research activities July 2019 to June 2024 | DoRA 2.0 | Database of Research Activity

<https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6544>

Queensland Health - Hospital and Health Service facility profiles

<https://www.health.qld.gov.au/services>

Research and Development Tax Incentive | business.gov.au

<https://business.gov.au/grants-and-programs/research-and-development-tax-incentive>

Further information

If you are an international sponsor seeking further information or guidance on conducting clinical trials in Queensland, our dedicated team is here to assist.

For sponsors based in the North America:

Alita Singer – alita.singer@tiq.qld.gov.au

For sponsors based in all other regions:

Shelly Lewis – shelly.lewis@tiq.qld.gov.au

We welcome your interest and look forward to helping you connect with Queensland's world-class clinical trial ecosystem.

Contribute to future editions

This directory is a work in progress and will continue to evolve. If you would like your Queensland-based clinical trial site or service offering to be considered for inclusion in future updates, please contact alita.singer@tiq.qld.gov.au

Disclaimer

The information presented in this report is distributed by the Queensland Government as an information source only and is not endorsed by the State of Queensland. The State of Queensland makes no statements, representation, or warranties about the accuracy or completeness of, and you should not rely on, any information contained in this publication. The Queensland Government disclaims all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages, and costs you might incur as a result of the information being inaccurate in any way, and for any reason.

Information provided in this document are non-confidential and with the consent of the individual companies. Information on our ecosystem and R&D benefits has been taken from publicly available information and was current at time of printing.

Currency conversions are approximate and were accurate at time of printing through <http://foreignxchange.com.au>

26_012. Issue date: June 2026



Connect with us today

For further information or help with your trade and investment enquiries, contact Trade and Investment Queensland.



TIO TRADE +
INVESTMENT
QUEENSLAND

[TIQ.QLD.GOV.AU](https://tqo.qld.gov.au)